Panuveitis in Sweet syndrome.

Ocular manifestations of Sweet syndrome, or acute febrile neutrophilic dermatosis, are usually limited to the anterior segment. We report the case of a patient with bilateral panuveitis and retinal vasculitis associated with Sweet syndrome. A 45-year-old Asian female with an undiagnosed febrile illness with rash presented with bilateral panuveitis with haemorrhagic occlusive retinal vasculitis. Skin biopsy confirmed Sweet Syndrome. Intraocular inflammation resolved with a combination of topical and systemic corticosteroids as well as intravenous cyclophosphamide, with resulting permanent severe right visual impairment. Although an uncommon condition, Sweet syndrome should be considered in any febrile patient with skin lesions and uveitis.

Loss of Pressure Control Resulting from Tube Bending during Glaucoma Drainage Tube Perforations.

PURPOSE: Tube perforations are a common method of achieving early intraocular pressure control with ligated glaucoma drainage devices (GDDs). Our purpose was to investigate how bending GDD tubes affects the performance of needle perforations. DESIGN: Experimental report. PARTICIPANTS: Twenty silicone GDD tubes attached to 27 G Rycroft cannulae tied with 7-0 Vicryl 10 mm from the cannulae tips. METHODS: Silicone GDD tubing was fitted over a 27 G Rycroft cannula and tied with a 7-0 suture 10 mm from the cannula tip. The tube was perforated 4 mm from the cannula tip with a 25 G needle (tube was kept straight). The tube was secured in a 50-mm water bath. Aqueous food dye was infused through the cannula from an adjustable height. The tube was observed under magnification while the height of the fluid column was adjusted to establish the pressure gradient at which the tube leaked dye (opening pressure) and ceased to leak (closing pressure), while the tube was held straight and bent 90 degrees. Measurements were repeated after a second perforation and a third perforation. Ten tubes were tested this way with 3 sequential slits. The entire experiment was repeated with another 10 tubes, but this time the tube was allowed to bend within the 3.5-mm open prongs of a needle holder during needle perforation. MAIN OUTCOME MEASURES: Opening and closing pressures. RESULTS: For each tube, the opening and closing pressures were similar and highly reproducible, but there was wide variation between tubes. In the tubes kept straight when perforated, the opening/closing pressure ranged from 5 to 25 cmH2O. The opening and closing pressures of slits made in the bent tube were significantly lower, frequently leaking at <1 cmH2O. Bending the tube after perforation could close a slit and prevent leakage at high perfusion pressure. The second and third successive perforations caused lower opening and closing pressures. CONCLUSIONS: Tube perforations behave like pressure-sensitive valves, opening whenever intraluminal pressure increases above a specific value. However, we found a large variation in the performance of fenestrations made with a 25-G hypodermic needle. Allowing the GDD tube to bend during needle perforation increases the risk of very low opening and closing pressures.

A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand.

PURPOSE: To produce an economic comparison of the iStent ab interno trabecular microbypass implant accompanying cataract surgery and selective laser trabeculoplasty (SLT) as first-line treatment versus topical medications for open-angle glaucoma in New Zealand in 2016. METHODS: The current annual costs of 19 available fully subsidised topical glaucoma medications by Pharmaceutical Management Agency (Pharmac) in 2016 were identified. Adjustments for pharmacist prescribing charges and previously described wastage levels were applied. The costs to perform iStent implantation and the cost to perform SLT were obtained from the local distributors, with the latter taking into account staff and consumable cost. Procedure costs divided by eye drops' cost produced a break-even level in equivalent years of eye drops use. RESULTS: The range of annual eye drop cost was NZD$42.25 to NZD$485.11, with an average of NZD$144.81. Comparison of annual eye drop cost with iStent cost revealed 3 of 19 (15.8%) drops breaking even within 5 years, 9 of 19 (47.3%) within 10 years, and 12 of 19 (63.2%) within 15 years. The cost of bilateral SLT performed by a consultant was NZD$102.30 (breaking even in 0.71 years). The equivalent cost for a registrar was NZD$97.59 (breaking even in 0.67 years). CONCLUSION: Economically, the iStent would appear to be a reasonably cost-effective treatment for glaucoma patients undergoing cataract surgery in a public healthcare setting in New Zealand, particularly for those using more expensive topical glaucoma medications, whilst SLT appears to be a worthwhile consideration as a first-line treatment for glaucoma in New Zealand.